Issued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, Dec. 12, 2025 /PRNewswire/ -- USANewsGroup.com News Commentary – Scientists developed an antibody treatment that…
CNSide Diagnostics now licensed in 48 U.S. States covering over 90% of the U.S. populationHOUSTON, Dec. 11, 2025 (GLOBE NEWSWIRE)…
IMA203CD8 is a second-generation PRAME cell therapy with enhanced pharmacology in ongoing Phase 1a dose escalationManageable tolerability across all dose…
MDNA11 demonstrates durable anti-tumor activity in phase-2 eligible expansion cohorts, enriched for immune checkpoint resistant melanoma, MSS endometrial cancer, MSI-H…
MDNA11 demonstrates durable anti-tumor activity in phase-2 eligible expansion cohorts, enriched for immune checkpoint resistant melanoma, MSS endometrial cancer, MSI-H…
MESA, ARIZONA / ACCESS Newswire / December 9, 2025 / Medical Care Technologies Inc. (OTC Pink:MDCE) is pleased to announce…
MESA, ARIZONA / ACCESS Newswire / December 8, 2025 / Medical Care Technologies Inc. (OTC Pink:MDCE) is thrilled to announce…
Long-term OS follow-up analysis of JUPITER-02 demonstrates significantly better and clinically meaningful improvement with toripalimab plus chemotherapy as 1st-line treatment…
A roundup of the most newsworthy healthcare press releases from PR Newswire, including new company mergers, Alzheimer's fundraising and advances…
AUSTIN, Texas, Dec. 04, 2025 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Chronic illnesses and rare disorders among older Americans represent…